Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters.

Authors

Matthieu Gregoire, Steven C Wallis, Paul G Williams, Hayoung Won, María Patricia Hernández-Mitre, Mohd H Abdul-Aziz, Jason A Roberts

Published in

Clinical pharmacokinetics. Aug 29, 2026. Epub Aug 29, 2026.

Abstract

Therapeutic drug monitoring (TDM) and pharmacokinetic studies of beta-lactam antibiotics in critically ill patients aim to define optimal dosing and require accurate measurement of unbound drug concentrations. This study compared the performance of two ultrafiltration devices, Centrifree and Amicon, for measuring unbound concentrations of cefepime, meropenem, flucloxacillin, piperacillin and tazobactam.
Non-specific binding (NSB) was specifically assessed in phosphate-buffered saline, and unbound concentrations were measured using a chromatographic method in both spiked plasma and plasma samples from critically ill patients, in order to compare the two ultrafiltration devices.
Centrifree exhibited no significant NSB for any antibiotics (≤ 15%), while Amicon displayed significant NSB for meropenem (26-61%), flucloxacillin (18-58%) and piperacillin (15-72%), resulting in lower unbound concentrations in both patient and spiked plasma samples compared to Centrifree. Additionally, piperacillin, and to a lesser extent flucloxacillin, demonstrated concentration-dependent NSB with Amicon. The comparative mean ± standard deviation of unbound fractions in intensive care unit (ICU) patients were as follows: cefepime, 0.85 ± 0.12 (Centrifree) versus 0.90 ± 0.10 (Amicon); meropenem, 0.87 ± 0.07 (Centrifree) versus 0.77 ± 0.05 (Amicon); flucloxacillin, 0.25 ± 0.13 (Centrifree) versus 0.18 ± 0.13 (Amicon); piperacillin, 0.91 ± 0.07 (Centrifree) versus 0.67 ± 0.13 (Amicon); and tazobactam, 0.97 ± 0.08 (Centrifree) versus 0.95 ± 0.08 (Amicon).
These findings underscore significant differences in results between ultrafiltration devices, depending on the drug, influenced by NSB. Such factors should be considered when developing methods for determining unbound concentrations of beta-lactam antibiotics.

PMID:
42667589
Bibliographic data and abstract were imported from PubMed on 30 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.